Efficacy of erlotinib as first-line maintenance therapy in patients with locally advanced or metastatic nonsmall cell lung cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy

Rajappa, Senthil; Chandra Doval, Dinesh; Biswas, Jaydip; Patil, Shekar; Somani, Naresh; Srinivasan, Sankar; Bondarde, Shailesh; S. Palwe, Nitin; Swarup, Binay

doi:10.4103/2278-330x.202573

Public

Efficacy of erlotinib as first-line maintenance therapy in patients with locally advanced or metastatic nonsmall cell lung cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy

Published in South Asian Journal of Cancer • Jan 1, 2017

Authors:

Senthil Rajappa

Dinesh Chandra Doval

Jaydip Biswas

Abstract

BACKGROUND: First-line maintenance with erlotinib in nonsmall cell lung cancer (NSCLC) patients without progression after four cycles of chemotherapy was well tolerated and significantly prolonged progression-free survival (PFS) compared with placebo. AIM AND DESIGN: This open-label, single arm, Pha...

Subject

Medicine

Internal medicine

Erlotinib

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!